Lung Cancer
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (20210033)
- Details
ClinicalTrials.gov ID:
NCT06311721
Diagnosis Type:
NA
USOR Number:
- Address
,
P: